England’s National Health Service has lifted restrictions on Janssen’s blood cancer drug Imbruvica (ibrutinib), after a journalist who was suffering from chronic lymphocytic leukaemia (CLL)
NICE has continued to reject Roche’s Perjeta (pertuzumab) in its use to prevent early-stage HER2-positive breast cancer from recurring after surgery, after reconsidering evidence in the lig
